Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 13/20 | 0.64 |
| ▸ | SRC | P12931 | 1/20 | 0.52 |
| ▸ | BRAF | P15056 | 4/20 | 0.52 |
| ▸ | TNNI3K | Q59H18 | 4/20 | 0.52 |
| ▸ | TTBK1 | Q5TCY1 | 1/20 | 0.51 |
| ▸ | TTBK2 | Q6IQ55 | 1/20 | 0.51 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.48 |
| ▸ | ABL1 | P00519 | 1/20 | 0.48 |
| ▸ | ABL2 | P42684 | 1/20 | 0.48 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.47 |
| ▸ | FADS1 | O60427 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4771041 | 0.91 | EGFR (0.62) | EGFRSRCBRAFTNNI3KTTBK1 | |
| SCHEMBL4770048 | 0.86 | EGFR (0.60) | EGFRSRCBRAFTNNI3KTTBK1 | |
| SCHEMBL27442803 | 0.85 | BRAF (0.62) | EGFRSRCBRAFTNNI3KTTBK1 | |
| SCHEMBL2461054 | 0.84 | BRAF (0.64) | EGFRSRCBRAFTNNI3KTTBK1 | |
| SCHEMBL7498606 | 0.84 | BRAF (0.66) | EGFRSRCBRAFTNNI3KTTBK1 | |
| SCHEMBL4771000 | 0.83 | BRAF (0.53) | EGFRBRAFTNNI3KTTBK1TTBK2 | |
| Bromide SCHEMBL7498610 | 0.83 | BRAF (0.65) | EGFRSRCBRAFTNNI3KTTBK1 | |
| SCHEMBL7492081 | 0.82 | EGFR (0.58) | EGFRBRAFTNNI3KTTBK1TTBK2 | |
| SCHEMBL7498074 | 0.81 | EGFR (0.57) | EGFRBRAFTNNI3KTTBK1TTBK2 | |
| SCHEMBL2459197 | 0.81 | EGFR (0.59) | EGFRSRCBRAFTNNI3KTTBK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1100778-C | Pyrrolopyrimidines and process for their preparation | NOVARTIS CO (CH) | 2003-02-05 | — | — | CN | claimed |
| EP-0836605-B1 | PYRROLOPYRIMIDINES AND PROCESSES FOR THE PREPARATION THEREOF | NOVARTIS AG (CH) | 2002-02-06 | — | — | EP | claimed |
| CN-1194647-A | Pyrrolopyrimidines and processes for preparation thereof | NOVARTIS CO (CH) | 1998-09-30 | — | — | CN | claimed |
| EP-0836605-A1 | PYRROLOPYRIMIDINES AND PROCESSES FOR THE PREPARATION THEREOF | Novartis AG (CH) | 1998-04-22 | — | — | EP | claimed |
| WO-1997002266-A1 | PYRROLOPYRIMIDINES AND PROCESSES FOR THE PREPARATION THEREOF | NOVARTIS AG (CH) | 1997-01-23 | — | — | WO | claimed |
| EP-0938486-B1 | SUBSTITUTED PYRROLOPYRIMIDINES AND PROCESSES FOR THEIR PREPARATION | NOVARTIS AG (CH) | 2008-01-16 | — | — | EP | disclosed |
| EP-0836605-B1 | PYRROLOPYRIMIDINES AND PROCESSES FOR THE PREPARATION THEREOF | NOVARTIS AG (CH) | 2002-02-06 | — | — | EP | disclosed |
| US-6180636-B1 | USED TO INHIBIT THE TYROSINE KINASE ACTIVITY OF THE RECEPTOR FOR THE EPIDERMAL GROWTH FACTOR AND C-ERBB2 KINASE AND CAN BE USED AS ANTITUMOR AGENTS | NOVARTIS AG (CH) | 2001-01-30 | — | — | US | disclosed |
| US-6140332-A | Pyrrolopyrimidines and processes for the preparation thereof | NOVARTIS AG (CH) | 2000-10-31 | — | — | US | disclosed |
| EP-0938486-A1 | SUBSTITUTED PYRROLOPYRIMIDINES AND PROCESSES FOR THEIR PREPARATION | Novartis AG (CH) | 1999-09-01 | — | — | EP | disclosed |
| EP-0836605-A1 | PYRROLOPYRIMIDINES AND PROCESSES FOR THE PREPARATION THEREOF | Novartis AG (CH) | 1998-04-22 | — | — | EP | disclosed |
| WO-1998007726-A1 | SUBSTITUTED PYRROLOPYRIMIDINES AND PROCESSES FOR THEIR PREPARATION | NOVARTIS AG (CH) | 1998-02-26 | — | — | WO | disclosed |
| WO-1997002266-A1 | PYRROLOPYRIMIDINES AND PROCESSES FOR THE PREPARATION THEREOF | NOVARTIS AG (CH) | 1997-01-23 | — | — | WO | disclosed |